Ocular Therapeutix™ to Participate in March Investor Conferences
Rhea-AI Summary
Ocular Therapeutix (NASDAQ: OCUL) will participate in multiple investor conferences in March 2026, including TD Cowen (March 2), Jefferies Biotech on the Beach (March 10), Citizens Life Sciences and Barclays (March 11) and RBC Ophthalmology (March 24).
Pravin U. Dugel, MD, Executive Chairman, President and CEO, will deliver several fireside chats. Live webcasts of TD Cowen, Citizens and RBC presentations will be available on the Investor Relations Events and Presentations page, with replays archived for at least 30 days.
Positive
- None.
Negative
- None.
News Market Reaction – OCUL
In the Feb 24 session, OCUL gained 6.48%, reflecting a notable positive market reaction. Argus tracked a peak move of +11.3% during that session. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 23 | Conference data preview | Positive | +8.1% | Planned detailed SOL-1 Phase 3 data presentations and investor webcast scheduling. |
| Feb 17 | Phase 3 topline data | Positive | -21.3% | SOL-1 Phase 3 superiority trial met primary and Week 52 durability endpoints. |
| Feb 13 | Data announcement date | Neutral | -2.0% | Scheduled webcast to review upcoming SOL-1 topline results and meeting presentation. |
| Feb 06 | Equity inducement grants | Neutral | +3.0% | Inducement stock options and RSUs granted to newly hired employees. |
| Feb 05 | Earnings and pipeline | Negative | +4.2% | 2025 results with lower revenue, higher R&D, and substantial net loss alongside strong cash. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent OCUL news has produced mixed reactions: positive clinical and financial updates sometimes saw negative or muted price moves, while scheduling or corporate updates have occasionally coincided with gains.
Over recent months, OCUL has focused on its SOL-1 Phase 3 program and financial positioning. On Feb 5, 2026, it reported 2025 results with revenue of $52.0M, a net loss of $265.9M, and cash of $737.1M. Subsequent news included inducement equity grants on Feb 6, SOL-1 topline data on Feb 17, and plans for detailed data presentations on Feb 23. Today’s investor-conference announcement continues the pattern of active investor communication around the SOL-1 program and broader strategy.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BEDFORD, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that the Company will participate in several upcoming investor conferences in March 2026.
TD Cowen 46th Annual Health Care Conference:
Date: Monday, March 2, 2026
Fireside Chat: 9:10 – 9:40 AM ET
Presenter: Pravin U. Dugel, MD, Executive Chairman, President and CEO
Location: Boston, MA
Jefferies Biotech on the Beach Summit:
Date: Tuesday, March 10, 2026
Location: Miami, FL
Citizens Life Sciences Conference 2026:
Date: Wednesday, March 11, 2026
Fireside Chat: 9:00 – 9:25 AM ET
Presenter: Pravin U. Dugel, MD, Executive Chairman, President and CEO
Location: Miami, FL
Barclays 28th Annual Global Healthcare Conference:
Date: Wednesday, March 11, 2026
Location: Miami, FL
RBC Capital Markets Ophthalmology Conference:
Date: Tuesday, March 24, 2026
Fireside Chat: 9:30 – 10:00 AM ET
Presenter: Pravin U. Dugel, MD, Executive Chairman, President and CEO
Location: Virtual
A live webcast of the TD Cowen, Citizens, and RBC fireside chats can be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page. A replay of the webcasts will be archived for at least 30 days following the presentation.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR).
Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Ocular is currently evaluating next steps for the OTX-TIC program.
Follow the Company on its website, LinkedIn, or X.
DEXTENZA® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.
Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com
